Fear of progression in idiopathic Parkinson ´s disease and the detection of influencing sociodemographic, clinical and neuropsychological factors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016021

Enrollment

240

Registered

2019-01-28

Start date

2019-01-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fear of progression G20

Interventions

Group 1: Cross-sectional study to assess the the prevalence of fear of progression in patients with idiopathic Parkinson's disease and to determine influencing sociodemographic, clinical and neuropsyc

single neuropsychological and clinical assessment regarding the specified outcomes

no intervention.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Centre of Parkinsonism and Movement Disorders, Paracelsus-Elena Hospital, Kassel, Germany); idiopathic Parkinson's disease with and without cognitive impairment diagnosed by a neurologist/psychiatrist; the patient is able to follow instructions and to complete questionnaires; age: above 50 years; normal or corrected-to normal vision and hearing; German as first language or excellent knowledge of the German language. For patients 50 years and older: Inpatient in the cooperating hospitals (Movement Disorders Clinic, Beelitz-Heilstätten, Germany For patients between 18 and 50 years: Outpatient care

Exclusion criteria

Exclusion criteria: Severe cognitive impairment that are not compatible with participating in the study (operationalized with the MoCA < 13 points): instructions cannot be realized; unable to consent in study participation; severe/life-threatening comorbidities that are not compatible with participating in the study; acute suicidal tendency.

Design outcomes

Primary

Measure	Time frame
Fear of progression (operationalized with the fear of progression questionnaire (PA-F) by Herschbach et al. (2005) and Waadt et al. (2011); the two-hour examination of this outcome takes place within one scheduled neuropsychological and clinical assessment.	—

Secondary

Measure	Time frame
Disease severity (UPDRS-III, Hoehn and Yahr-Stage); activities of daily living (UPDRS-II); pain (visual analogue scale); globale cognition (MoCA); executive functions (RWT, Key Search, TMT A and B); reasoning (LPS 50+, Subtest 4); depression (HADS-D); anxiety (HADS-D); hypochondria (Whiteley-Index); personality (NEO-FFI); quality of life (PDQ-8); sense of coherence (Sense of Coherence-Scale, SOC-L9); coping/introspection/self-verbalisation/hope/social support/motivation to change (FERUS); healthy literacy (HLS-EU-Q47); knowledge about Parkinson's disease (self-rating on a multi-level analogue scale); the examination of these outcomes takes place within one scheduled two-hour neuropsychological and clinical assessment.	—

Measure

Time frame

Disease severity (UPDRS-III, Hoehn and Yahr-Stage); activities of daily living (UPDRS-II); pain (visual analogue scale); globale cognition (MoCA); executive functions (RWT, Key Search, TMT A and B); reasoning (LPS 50+, Subtest 4); depression (HADS-D); anxiety (HADS-D); hypochondria (Whiteley-Index); personality (NEO-FFI); quality of life (PDQ-8); sense of coherence (Sense of Coherence-Scale, SOC-L9); coping/introspection/self-verbalisation/hope/social support/motivation to change (FERUS); healthy literacy (HLS-EU-Q47); knowledge about Parkinson's disease (self-rating on a multi-level analogue scale); the examination of these outcomes takes place within one scheduled two-hour neuropsychological and clinical assessment.

—

Countries

Germany

Contacts

Public ContactAnn-Kristin Folkerts

Medizinische Psychologie | Neuropsychologie und Gender Studies, Uniklinik Köln

ann-kristin.folkerts@uk-koeln.de+49 221 478-96248

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026